Treatment for tumors driven by metabolic dysfunction
US11273142B2 · kind B2 · utility
2Cited by
42References
38Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 7, 2020 |
| Grant date | Mar 15, 2022 |
| Priority date | — |
| Expiry date | May 7, 2040 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P35/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure relates to modified or polymer conjugated MetAP2 inhibitors. The present disclosure also relates to methods of treating metabolically-driven diseases and disorders, such as certain cancers.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.